检索范围:
排序: 展示方式:
Progress and challenges in RET-targeted cancer therapy
《医学前沿(英文)》 2023年 第17卷 第2期 页码 207-219 doi: 10.1007/s11684-023-0985-y
关键词: pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug resistance
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
null
《医学前沿(英文)》 2012年 第6卷 第1期 页码 67-78 doi: 10.1007/s11684-012-0176-8
Antitumor angiogenic therapy has been shown promising in the treatment of several advanced cancers since the approval of the first antiangiogenic drug Avastin in 2004. Although the current antiangiogenic drugs reduce the density of tumor blood vessels and result in tumor shrinkage at the early stage of treatment, recent studies have shown that antiangiogenic therapy has transient and insufficient efficacy, resulting in tumor recurrence in patients after several months of treatment. Blockage of blood and oxygen supplies creates a hypoxic and acidic microenvironment in the tumor tissues, which fosters tumor cells to become more aggressive and metastatic. In 2001, Jain proposed tumor vascular normalization as an alternative approach to treating cancers based on the pioneering work on tumor blood vessels by several other researchers. At present, normalizing the disorganized tumor vasculature, rather than disrupting or blocking them, has emerged as a new option for anticancer therapy. Preclinical and clinical data have shown that tumor vascular normalization using monoclonal antibodies, proteins, peptides, small molecules, and pericytes resulted in decreased tumor size and reduced metastasis. However, current tumor vascular normalizing drugs display moderate anticancer efficacy. Accumulated data have shown that a variety of vasculogenic/angiogenic tumor cells and genes play important roles in tumor neovascularization, growth, and metastasis. Therefore, multiple-targeting of vasculogenic tumor cells and genes may improve the efficacy of tumor vascular normalization. To this end, the combination of antiangiogenic drugs with tumor vascular normalizing therapeutics, as well as the integration of Western medicine with traditional Chinese medicine, may provide a good opportunity for discovering novel tumor vascular normalizing drugs for an effective anticancer therapy.
关键词: angiogenesis vasculogenesis neovascularization tumor vasculature normalization traditional Chinese medicine
Complex interplay between tumor microenvironment and cancer therapy
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 426-439 doi: 10.1007/s11684-018-0663-7
Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist within and around the tumor mass. The TME is highly dynamic and its importance in different stages of cancer progression has been well recognized. A growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses. TME is significantly remodeled upon cancer therapies, and such change either enhances the responses or induces drug resistance. Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME to improve therapeutic responses are under developing. In this review, we provide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer treatments. We also summarize the strategies that aim to enhance therapeutic efficacy by modulating TME.
关键词: tumor microenvironment therapy response treatment resistance
《医学前沿(英文)》 2023年 第17卷 第4期 页码 699-713 doi: 10.1007/s11684-022-0972-8
关键词: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment tumor-associated macrophage metabolism
Multi-target combinatory strategy to overcome tumor immune escape
《医学前沿(英文)》 2022年 第16卷 第2期 页码 208-215 doi: 10.1007/s11684-022-0922-5
关键词: immune checkpoints multi-target immune escape immune-related adverse events combination therapy
《医学前沿(英文)》 2022年 第16卷 第5期 页码 784-798 doi: 10.1007/s11684-021-0911-0
关键词: uveal melanoma mutant GNAQ/11 palmitoylation BCL2 combination target therapy
Yinlong Zhang, Guangna Liu, Jingyan Wei, Guangjun Nie
《医学前沿(英文)》 2018年 第12卷 第6期 页码 667-677 doi: 10.1007/s11684-017-0583-y
关键词: platelet-mimicking delivery systems tumor-associated platelets cancer therapy EPR effect
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a
《医学前沿(英文)》 2022年 第16卷 第3期 页码 322-338 doi: 10.1007/s11684-021-0901-2
关键词: cancer immunotherapy chimeric antigen receptor solid tumors tumor-associated antigen glycosylation O-glycans adoptive cell therapy
NADPH oxidase and reactive oxygen species as signaling molecules in carcinogenesis
Gang WANG
《医学前沿(英文)》 2009年 第3卷 第1期 页码 1-7 doi: 10.1007/s11684-009-0018-5
关键词: free radicals tumor phox cell proliferation cancer therapy
Antitumor immunity of human SART3 gene vaccine against mouse tumor
HE Yu, YANG Shuhua, LIU Yong, LI Tao
《医学前沿(英文)》 2008年 第2卷 第1期 页码 51-57 doi: 10.1007/s11684-008-0010-5
关键词: antitumor therapy occurrence implantation DNA vaccine SART3 DNA
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
《医学前沿(英文)》 2022年 第16卷 第3期 页码 307-321 doi: 10.1007/s11684-022-0927-0
关键词: tumor immunotherapy immune checkpoint inhibitor antibiotics gut microbiota drug–drug interaction
null
《医学前沿(英文)》 2016年 第10卷 第1期 页码 52-60 doi: 10.1007/s11684-016-0433-3
Hepatocellular carcinoma (HCC) is a lethal liver malignancy worldwide. In this study, we reported that protein phosphatase magnesium-dependent 1δ (PPM1D) was highly expressed in the majority of HCC cases (approximately 59%) and significantly associated with high serum α-fetoprotein (AFP) level (P= 0.044). Kaplan-Meier and Cox regression data indicated that PPM1D overexpression was an independent predictor of HCC-specific overall survival (HR, 2.799; 95% CI, 1.346–5.818, P = 0.006). Overexpressing PPM1D promoted cell viability and invasion, whereas RNA interference-mediated knockdown of PPM1D inhibited proliferation, invasion, and migration of cultured HCC cells. In addition, PPM1D suppression by small interfering RNA decreased the tumorigenicity of HCC cells in vivo. Overall, results suggest that PPM1D is a potential prognostic marker and therapeutic target for HCC.
关键词: PPM1D hepatocellular carcinoma prognosis target therapy
Heterogeneity of the tumor immune microenvironment and clinical interventions
《医学前沿(英文)》 2023年 第17卷 第4期 页码 617-648 doi: 10.1007/s11684-023-1015-9
Proteins moonlighting in tumor metabolism and epigenetics
Lei Lv, Qunying Lei
《医学前沿(英文)》 2021年 第15卷 第3期 页码 383-403 doi: 10.1007/s11684-020-0818-1
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
《医学前沿(英文)》 2010年 第4卷 第3期 页码 290-293 doi: 10.1007/s11684-010-0093-7
关键词: breast cancer postmenopausal hormone therapy unopposed estrogen therapy combined estrogen-progestin therapy
标题 作者 时间 类型 操作
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
null
期刊论文
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy
期刊论文
Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal
期刊论文
Platelet membrane-based and tumor-associated platelet- targeted drug delivery systems for cancer therapy
Yinlong Zhang, Guangna Liu, Jingyan Wei, Guangjun Nie
期刊论文
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a
期刊论文
Antitumor immunity of human SART3 gene vaccine against mouse tumor
HE Yu, YANG Shuhua, LIU Yong, LI Tao
期刊论文
Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma
null
期刊论文